AURA
NASDAQAura Biosciences Inc.
Price$6.24-0.18 (-2.88%)
01:30 PM05:15 PM
News · 26 weeks43-80%
2025-12-142026-06-07
Mix2990d
- SEC Filings14(48%)
- Other6(21%)
- Insider4(14%)
- Offering4(14%)
- Leadership1(3%)
Latest news
25 items- PRAura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal MelanomaEnrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027. "Completing enrollment in our Pha
- INSIDEROfficer Holles Natalie C. was granted 1,153,962 shares (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- PRAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA) ("Aura" or the "Company"), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, "Inducement Awards") were granted to Natalie Holles, Aura's new Chief Executive Officer and President, on May 19, 2026 (the "Grant Date"). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles' offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Awards consist of (i) non-qualified stock
- SECSEC Form S-8 filed by Aura Biosciences Inc.S-8 - Aura Biosciences, Inc. (0001501796) (Filer)
- SECSEC Form SCHEDULE 13G filed by Aura Biosciences Inc.SCHEDULE 13G - Aura Biosciences, Inc. (0001501796) (Subject)
- PRAura Biosciences to Participate in Upcoming Investor ConferencesBOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026. Fireside Chat at 12:00 p.m. ET TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026. Fireside Chat at 1:30 p.m. ET The live webcasts of the fireside chats will be available on the "Investors & Media" page under the "Events &
- INSIDERLarge owner Matrix Capital Management Company, Lp sold $39,044,987 worth of shares (6,922,870 units at $5.64) (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECSEC Form 10-Q filed by Aura Biosciences Inc.10-Q - Aura Biosciences, Inc. (0001501796) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aura Biosciences Inc.SCHEDULE 13D/A - Aura Biosciences, Inc. (0001501796) (Subject)
- SECAura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsPhase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. "We are entering a pivotal period for Aura as
- INSIDERSEC Form 3 filed by new insider Holles Natalie C.3 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECAura Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesBOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of $0.000
- SECAura Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Results of Operations and Financial Condition8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded WarrantsBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 39,591,000 shares of its common stock and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant. In addition, Aura has granted the underwriters a 30-day option to purchase up to an additional 6,508,650 shares of its common stock on the same terms and conditions
- SECSEC Form DEFA14A filed by Aura Biosciences Inc.DEFA14A - Aura Biosciences, Inc. (0001501796) (Filer)
- SECSEC Form S-3MEF filed by Aura Biosciences Inc.S-3MEF - Aura Biosciences, Inc. (0001501796) (Filer)
- SECSEC Form 424B5 filed by Aura Biosciences Inc.424B5 - Aura Biosciences, Inc. (0001501796) (Filer)
- SECAura Biosciences Inc. filed SEC Form 8-K: Leadership Update, Other Events, Regulation FD Disclosure8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Aura intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock (and shares of common stock underlying pre-funded warrants) offered in the public offering on the same terms and conditions. All of the
- PRAura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment CompletionNatalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors Acceleration in patient screening driving Phase 3 CoMpass trial enrollment to near completion BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that its Board of Directors has appointed Natalie Holles as Chief Executive Officer and President and member of the Board of Directors, effective April 30, 2026. Ms. Holles succe
- SECSEC Form DEFA14A filed by Aura Biosciences Inc.DEFA14A - Aura Biosciences, Inc. (0001501796) (Filer)
- SECSEC Form DEF 14A filed by Aura Biosciences Inc.DEF 14A - Aura Biosciences, Inc. (0001501796) (Filer)
- INSIDERSEC Form 4 filed by Kilroy Conor4 - Aura Biosciences, Inc. (0001501796) (Issuer)
AURA FAQ
7 questionsWhat does Aura Biosciences Inc. do?
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Where does AURA stock trade?
Aura Biosciences Inc. (AURA) is listed on NASDAQ.What sector and industry is AURA in?
Aura Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Aura Biosciences Inc. go public?
Aura Biosciences Inc. (AURA) completed its IPO in 2021.What are analysts saying about AURA?
Aura Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform with a $1300.00 price target on 2025-11-26. Recent price targets range from $1300.00 to $4000.00.What companies are similar to AURA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AURA side-by-side with any of them on Quantisnow.How can I track AURA on Quantisnow?
Quantisnow aggregates Aura Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AURA to receive live email and push alerts on every new disclosure.